Document 0869
 DOCN  M9550869
 TI    Comparison of metabolism and in vitro antiviral activity of stavudine
       versus other 2',3'-dideoxynucleoside analogues.
 DT    9505
 AU    Sommadossi JP; Department of Pharmacology, University of Alabama at
       Birmingham; 35294.
 SO    J Infect Dis. 1995 Mar;171 Suppl 2:S88-92. Unique Identifier : AIDSLINE
       MED/95164994
 AB    2',3'-dideoxynucleosides are the principal drugs used to treat AIDS and
       are the only drugs thus far with demonstrated clinical benefits in
       patients with human immunodeficiency virus (HIV) infection. Although
       nucleoside analogues are structurally similar and have common mechanisms
       of action, each drug has unique molecular, cellular, and clinical
       features. For example, 3'-azido-3'-deoxythymidine (zidovudine) and
       3'-deoxy-2',3'-didehydrothymidine (stavudine) have similar in vitro
       anti-HIV activity but differ in their tendency to produce bone marrow
       suppression. Stavudine has been shown to be less myelosuppressive than
       zidovudine. With the exception of zidovudine, most of the clinically
       evaluated nucleoside analogues, including 2',3'-dideoxyinosine
       (didanosine), 2',3'-dideoxycytidine (zalcitabine), and stavudine,
       produce dose-dependent peripheral neuropathy. However, recent studies
       suggest that neuropathy induced by stavudine may be mediated by
       mechanisms different from those of didanosine and zalcitabine.
 DE    Animal  Comparative Study
       Dideoxynucleosides/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE  Human  HIV
       Infections/*DRUG THERAPY/METABOLISM  In Vitro
       Stavudine/METABOLISM/PHARMACOLOGY/*THERAPEUTIC USE  Structure-Activity
       Relationship  Support, Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).